bluebird bio
NEWS
The company has snapped up manufacturing space in North Carolina’s Research Triangle Park to internally produce lentiviral vector for the company’s gene and cell therapies.
The drug developed by Alkermes took a lot of flack but proved effective in a recent study.
At 14.1%, healthcare is the third largest weighted sector in the S&P 500 index, and with 76 million baby boomers getting older and living longer, owning healthcare stocks in your portfolio makes sense.
Bluebird is making forays into the CAR-T immuno-oncology market, although it has yet to bring a product to market.
Immuno-oncology and gene therapy has been a hot field for the last few years, and the approval of the first CAR-T therapies has only set the kindling ablaze.
On Oct. 13, the FDA’s Cellular, Tissue and Gene Therapies Advisory Committee unanimously recommended Spark’s Luxturna in a vote of 16 to 0.
JOBS
IN THE PRESS
bluebird bio, Inc. today announced that members of the management team will present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology, Wednesday, October 3, at 3:30 p.m. ET at the Lotte New York Palace, New York City.
More than 100 life sciences experts will share best practices to unify processes in clinical, regulatory, and quality
Updated Efficacy and Safety Data Consistent with Previously Reported Phase 2/3 Starbeam Results
bluebird bio, Inc. today announced that members of the management team will present at the following upcoming investor conferences:
bluebird bio, Inc. and Gritstone Oncology, Inc. today announced a collaboration to research, develop and commercialize products for the treatment of cancer using cell therapy.
The collaborators will specifically leverage Regeneron’s VelociSuite® platform technologies for the discovery and characterization of fully human antibodies
Regeneron Pharmaceuticals, Inc. and bluebird bio, Inc. announced a collaboration to apply their respective technology platforms to the discovery, development and commercialization of novel immune cell therapies for cancer.
Data Include Updates from Phase 2/3 Starbeam (ALD-102) Study of Lenti-D for Cerebral Adrenoleukodystrophy (CALD) and Initial Data from Ongoing Observational Study (ALD-103) of Allogeneic Hematopoietic Stem Cell Transplant for CALD
bluebird bio, Inc. announced that members of the management team will present at the 2018 Wedbush PacGrow Healthcare Conference, Tuesday, August 14, at 8:35 a.m. ET at the Parker New York Hotel, New York City.
bluebird bio, Inc. (Nasdaq: BLUE) today announced the closing of its previously announced underwritten public offering of 3,892,308 shares of its common stock, including 507,692 shares of common stock sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a public offering price of $162.50 per share.